Media Release
Health Sciences Authority approves Novartis Kisqali® for the treatment of Stage IV metastatic breast cancer in postmenopausal women
Health Sciences Authority approves Novartis Kisqali® for the treatment of Stage IV metastatic breast cancer in postmenopausal women
Kisqali (LEE011/ Ribociclib), a CDK4/6 inhibitor, in combination…